Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-22-020848
Filing Date
2022-08-04
Accepted
2022-08-04 07:02:13
Documents
73
Period of Report
2022-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q vnda-20220630.htm   iXBRL 10-Q 1185592
2 EX-31.1 vndaex311630202210q.htm EX-31.1 10582
3 EX-31.2 vndaex312630202210q.htm EX-31.2 10206
4 EX-32.1 vndaex321630202210q.htm EX-32.1 6767
  Complete submission text file 0001628280-22-020848.txt   5695465

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT vnda-20220630.xsd EX-101.SCH 44392
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT vnda-20220630_cal.xml EX-101.CAL 65206
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT vnda-20220630_def.xml EX-101.DEF 184108
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT vnda-20220630_lab.xml EX-101.LAB 507275
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT vnda-20220630_pre.xml EX-101.PRE 340619
67 EXTRACTED XBRL INSTANCE DOCUMENT vnda-20220630_htm.xml XML 888926
Mailing Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037
Business Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037 202-734-3400
Vanda Pharmaceuticals Inc. (Filer) CIK: 0001347178 (see all company filings)

EIN.: 030491827 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-34186 | Film No.: 221134583
SIC: 2834 Pharmaceutical Preparations